PriceTargets.com logo

IMARA - IMRA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00 As of 02/23/2023 05:00 PM ET
+0 (0.00%)
Get New IMARA Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMRA

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for IMARA in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for IMRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in IMARA. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/25/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/23/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2022HC WainwrightReiterated RatingNeutralLow
4/6/2022SVB LeerinkReiterated RatingOutperform ➝ Market PerformMedium
4/5/2022CitigroupDowngradeBuy ➝ NeutralHigh
3/16/2022SVB LeerinkLower TargetOutperform$148.00 ➝ $124.00High
1/6/2022Morgan StanleyLower TargetEqual Weight$48.00 ➝ $16.00Medium
11/30/2021HC WainwrightInitiated CoverageBuy$40.00High
8/11/2021Morgan StanleyDowngradeOverweight ➝ Equal Weight$132.00 ➝ $48.00High
4/19/2021Morgan StanleyLower TargetOverweight$136.00 ➝ $132.00Medium
3/8/2021Morgan StanleyLower TargetOverweight$140.00 ➝ $136.00High
3/8/2021SVB LeerinkLower TargetOutperform$236.00 ➝ $168.00High
8/17/2020CitigroupUpgradeNeutral ➝ Buy$136.00 ➝ $120.00High
6/30/2020CitigroupDowngradeBuy ➝ Neutral$120.00 ➝ $136.00High
6/12/2020SVB LeerinkBoost TargetOutperform$108.00 ➝ $256.00High
5/8/2020SVB LeerinkBoost TargetOutperform$100.00 ➝ $108.00High
4/6/2020CitigroupInitiated CoverageBuy$120.00Medium
4/6/2020CowenInitiated CoverageOutperform$100.00Low
4/6/2020SVB LeerinkInitiated CoverageOutperform$100.00Low
4/6/2020Morgan StanleyInitiated CoverageOverweight$140.00Low
(Data available from 4/18/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/18/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
IMARA logo
IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2-related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $17.12
Low: $6.32
High: $25.28

52 Week Range

Now: N/A

Volume

271,700 shs

Average Volume

138,364 shs

Market Capitalization

$165.80 million

P/E Ratio

126.40

Dividend Yield

N/A

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of IMARA?

The following Wall Street analysts have issued stock ratings on IMARA in the last twelve months:
View the latest analyst ratings for IMRA.

What is the current price target for IMARA?

0 Wall Street analysts have set twelve-month price targets for IMARA in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for IMARA in the next year.
View the latest price targets for IMRA.

What is the current consensus analyst rating for IMARA?

IMARA currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for IMRA.

What other companies compete with IMARA?

Other companies that are similar to IMARA include Regulus Therapeutics, scPharmaceuticals, Renovaro, Skye Bioscience and Inventiva. Learn More about companies similar to IMARA.

How do I contact IMARA's investor relations team?

IMARA's physical mailing address is 116 HUNTINGTON AVENUE. 6TH FLOOR, BOSTON MA, 02116. The official website for IMARA is www.imaratx.com. Learn More about contacing IMARA investor relations.